CD19 is currently the most widely used target (Blinatumomab), but bispecific antibodies redirecting T cells against CD20 (Mosunetuzumab) have recently been approved for follicular lymphoma and new antibodies targeting BCMA for multiple myeloma are likely to enter clinical practice in the near future [95]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.